Associations between XPD Asp312Asn Polymorphism and Risk of Head and Neck Cancer: A Meta-Analysis Based on 7,122 Subjects by Hu, Yuan Yuan et al.
Associations between XPD Asp312Asn Polymorphism
and Risk of Head and Neck Cancer: A Meta-Analysis
Based on 7,122 Subjects
Yuan Yuan Hu
1, Hua Yuan
2, Guang Bing Jiang
3, Ning Chen
2, Li Wen
4, Wei Dong Leng
1, Xian Tao Zeng
1,
Yu Ming Niu
1,2*
1Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China, 2Institute of Dental Research, Nanjing Medical University,
Nanjing, People’s Republic of China, 3Department of Radiology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China, 4Department of
Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, People’s Republic of China
Abstract
Background: To investigate the association between XPD Asp312Asn polymorphism and head and neck cancer risk through
this meta-analysis.
Methods: We performed a meta-analysis of 9 published case-control studies including 2,670 patients with head and neck
cancer and 4,452 controls. An odds ratio (OR) with a 95% confidence interval (CI) was applied to assess the association
between XPD Asp312Asn polymorphism and head and neck cancer risk.
Results: Overall, no significant association between XPD Asp312Asn polymorphism and head and neck cancer risk was
found in this meta-analysis (Asn/Asn vs. Asp/Asp: OR=0.95, 95%CI=0.80–1.13, P=0.550, Pheterogeneity=0.126; Asp/Asn vs.
Asp/Asp: OR=1.11, 95%CI=0.99–1.24, P=0.065, Pheterogeneity=0.663; Asn/Asn+Asp/Asn vs. Asp/Asp: OR=1.07,
95%CI=0.97–1.19, P=0.189, Pheterogeneity=0.627; Asn/Asn vs. Asp/Asp+Asp/Asn: OR=0.87, 95%CI=0.68–1.10, P=0.243,
Pheterogeneity=0.089). In the subgroup analysis by HWE, ethnicity, and study design, there was still no significant association
detected in all genetic models.
Conclusions: This meta-analysis demonstrates that XPD Asp312Asn polymorphism may not be a risk factor for developing
head and neck cancer.
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Introduction
Head and neck cancers (HNC) constitute about 5% of all
cancers recorded in the US, and the incidence is increasing in
most developed and developing countries. These cancers have
been estimated to be about six times more common among
smokers than non-smokers and are most common in males over 50
years old [1,2], which increases to about 15 times if the smokers
are also heavy drinkers [3,4]. Although many measures had been
done to improve the diagnosis and treatments, the prognosis was
still poor.
Many environmental factors, such as radiation, diet,
smoking, and endogenous or exogenous estrogens, are
associated with DNA damage. Unrepaired or misrepaired
DNA results in gene mutations, chromosomal alterations, and
genomic instability. Several studies have suggested that genes
involved in DNA repair play a crucial role in protecting against
mutations. Patients with certain cancers have reduced capac-
ities for DNA repair. Similarly, the enzymes of the nucleotide
excision repair (NER) pathway have been implicated in cancer.
Associations between polymorphisms in several DNA repair
genes and the risks of several types of cancer have been
extensively examined. Many epidemiologic cancer studies have
focused on single nucleotide polymorphisms (SNPs) in genes in
the NER pathway such as XPD, ERCC1,a n dXPC [5]. The
XPD protein is a DNA helicase and is an essential part of the
TFIIH transcription factor complex. Some studies have
suggested that XPD polymorphisms may be associated with
reduced DNA repair because of a possible reduction in helicase
activity [6,7]. One of the common XPD polymorphisms in the
coding regions is Asp312Asn in exon 10. The functional
significance is not yet completely clear, although the amino
acid mutations in exon 10 give rise to a loss of an acidic residue
and a complete change in the electronic configuration of the
amino acid [8,9].
The first study on the relationship between HNC and XPD
Asp312Asn polymorphism was conducted by Sturgis et al. [10].
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Asp312Asn polymorphism and HNC. Since then, a lot of studies
have confirmed or refuted this finding [11–18]. In 2010, a recent
meta-analysis was conducted by Flores-Obando et al. [19]
demonstrated that increased HNC risk is associated with XPD
Asp312Asn polymorphism. Worthy of note, that meta-analysis
included five studies were conducted in Caucasian populations
and one in an Asian population [10–15]. Today, nine case-control
studies on XPD Asp312Asn polymorphism and HNC risk have
been published. A comprehensive meta-analysis is needed to
provide an updated approach on the overall relationship.
Subgroup analyses were also performed on Caucasian and Asian
populations to investigate ethnicity-specific effects.
Methods
Search strategy
The PubMed database was searched with terms ‘‘head and
neck cancer’’, ‘‘oral cancer’’, ‘‘oropharyngeal cancer’’, ‘‘laryngeal
cancer’’, ‘‘pharyngeal cancer’’, ‘‘XPD’’, ‘‘excision repair cross-
complementing group 2’’, ‘‘polymorphism’’, and the combined
phrases for all genetic studies on the relationship between XPD
polymorphism and HNC risk from 2000, when the first study of
the association between XPD Asp312Asn polymorphism and
HNC risk was reported, to October 2011. We also used the
‘‘Related Articles’’ option in PubMed to identify additional
studies on the same topic. Reference lists in retrieved articles were
also screened for. All selected studies complied with the following
three criteria: (a) case–control study on the XPD Asp312Asn
polymorphism and HNC risk; (b) sufficient published data for
estimating the odds ratio (OR) with 95% confidence interval (CI);
(c) For multiple publications reporting on the same data or
overlapping data, the largest or most recent publication was
selected [20].
Data extraction
Two investigators (Hu and Yuan) independently extracted the
following data from each included publication: the first author’s
name, publication data, sources of controls, racial descent of the
study population (categorized as either Asian or Caucasian),
genotyping method, number of cases, cases and controls with
different genotypes, and Hardy-Weinberg equilibrium(HWE).
Statistical analysis
Crude ORs with 95% CIs were computed to assess the strength
of the correlation between the XPD Asp312Asn polymorphism and
HNC risk. The pooled ORs were performed for codominant
model (Asn/Asn vs. Asp/Asp,Asp/Asn vs. Asp/Asp), dominant
model (Asn/Asn+Asp/Asn vs. Asp/Asp), and recessive model
(Asn/Asn vs. Asp/Asp+Asp/Asn), respectively. In the subgroup
analysis, statistical analysis was conducted on Asians and
Caucasians. Heterogeneity assumption was assessed by the chi-
square based Q-test [21]. The pooled OR estimation of each study
was calculated by the fixed-effects model (the Mantel–Haenszel
method) when P.0.10. Otherwise, the random-effects model (the
DerSimonian and Laird method) was used [22]. The potential
publication bias was estimated by the modified Egger’s linear
regression test, which proposed by Harbord et al. [23]. Statistical
analysis was performed using STATA version 11.0 (Stata
Corporation, College Station, TX, USA) and Review Manage
(v.4.2; Oxford, England), using two-sided P-values, with P,0.05
considered statistically significant.
Results
Study characteristic
This meta-analysis is guided by the PRISMA statement
(Checklist S1). A total of 49 relevant studies were identified
(Figure 1). After carefully review, nine eligible case-control studies
on the relationship between XPD Asp312Asn polymorphism and
HNC risk were included in this meta-analysis [10–18]. Table 1
presents the main characteristics of these studies. Seven studies
involved Caucasian populations [10–12,14–16,18], whereas two
studies involved Asians [13,17]. Diverse genotyping methods were
used, including PCR-SSCP, PCR-RFLP, Taqman, Real-time
PCR and SEB PCR. All studies indicated that the genotypic
distribution of the controls was consistent with HWE except one
[17].
Meta-analysis
The main results of this meta-analysis and the heterogeneity test
are shown in Table 2. Overall, no significant relationship was
observed between XPD Asp312Asn polymorphism and HNC risk
in the total populations (for Asn/Asn vs. Asp/Asp: OR=0.95,
95%CI=0.80–1.13, P=0.550, Pheterogeneity=0.126; Asp/Asn vs.
Asp/Asp: OR=1.11, 95%CI=0.99–1.24, P=0.065, Pheterogeneity
=0.663; Asn/Asn+Asp/Asn vs. Asp/Asp: OR=1.07, 95%CI=0.97–
1.19, P=0.189, Pheterogeneity=0.627; Asn/Asn vs. Asp/Asp+Asp/Asn:
OR=0.87, 95%CI=0.68–1.10, P=0.243, Pheterogeneity=0.089).
Similarly, in the succeeding analysis of HWE studies, no significant
association was found between XPD Asp312Asn polymorphism and
Figure 1. Flow diagram of the study selection process.
doi:10.1371/journal.pone.0035220.g001
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1.14, P=0.593, Pheterogeneity=0.120; Asp/Asn vs. Asp/Asp:
OR=1.11, 95%CI=0.99–1.24, P=0.089, Pheterogeneity=0.586;
Asn/Asn+Asp/Asn vs. Asp/Asp: OR=1.07, 95%CI=0.96–1.19,
P=0.219, Pheterogeneity=0.528; Asn/Asn vs. Asp/Asp+Asp/Asn:
OR=0.82, 95%CI=0.69–1.11, P=0.278, Pheterogeneity=0.082).
Finally, in the stratified analysis of ethnicity and study design, we
also did not find any significant association between XPD
Asp312Asn polymorphism and HNC.
Sensitivity analysis
A single study involved in the meta-analysis was deleted each
time to reflect the influence of the individual dataset to the pooled
ORs. The analysis results demonstrate a borderline increased risk
after excluding the studies that in Asp/Asn vs. Asp/Asp model
[14,16,18] (Figure 2). The other corresponding pooled ORs were
not materially altered (data not shown), indicating that our results
are statistically robust.
Publication bias
Funnel plot and modified Egger’s test were performed to
estimate the publication bias of literature. The shapes of the funnel
plots in all genetic models did not reveal any evidence of obvious
asymmetry. Figure 3 shows the shapes of the funnel plots of
codominant model (Asp/Asn vs. Asp/Asp), used in the studies for
examining all populations. The result was further supported by
analysis via modified Egger’s tests. No significant publication bias
was found in this meta-analysis (P=0.093 for Asn/Asn vs. Asp/
Asp; P=0.370 for Asp/Asn vs. Asp/Asp; P=0.173 for Asn/
Asn+Asp/Asn vs. Asp/Asp; P=0.215 for Asn/Asn vs. Asp/
Asp+Asp/Asn).
Discussion
Today, genetic susceptibility to cancer has attracted growing
attention to the study of gene polymorphisms involved in
tumorigenesis. The XPD gene has been mapped to chromosome
19q13.3 and it is composed of 23 exons. Germline mutations in
the XPD gene can result in xeroderma pigmentosum and other
diseases. The XPD protein is involved in transcription-coupled
NER and is an integral member of the basal transcription factor
BTF2/TFIIH complex.
The Asp to Asn change at position 312 of XPD changes the
electronic configuration of amino acid and alters the interaction
between XPD protein and its helicase activator [6]. Wolfe et al.
Table 1. Characteristics of case-control studies on XPD Asp312Asn polymorphism and HNC risk included in the meta-analysis.
F rst
author Year
Racial
descent
Source of
controls Case Control Genotype distribution
Genotying
type
P for
HWE
{
Case Control
Asp/Asp Asp/Asn Asn/Asn Asp/Asp Asp/Asn Asn/Asn
Sturgis 2002 Caucasian Hospital-based 313 313 123 165 25 142 135 36 PCR-SSCP 0.650
Matullo 2006 Caucasian Population-based 82 1094 32 46 4 418 506 170 TaqMan 0.411
An 2007 Caucasian Hospital-based 829 854 330 395 104 370 386 98 PCR-RFLP 0.860
Majumder 2007 Asian Hospital-based 305 387 152 119 34 205 146 36 PCR-RFLP 0.183
Harth 2008 Caucasian Hospital-based 311 298 113 158 40 101 145 52 Real-time PCR 0.997
Abbasi 2009 Caucasian Population-based 246 644 93 119 34 258 304 82 Real-time PCR 0.606
Jelonek 2010 Caucasian Hospital-based 29 58 10 14 5 14 36 8 PCR-RFLP 0.052
Ji 2010 Asian Hospital-based 264 342 235 29 0 309 30 3 SBE PCR 0.026
Gugatschka 2011 Caucasian Population-based 291 462 116 133 42 171 208 83 TaqMan 0.158
doi:10.1371/journal.pone.0035220.t001
Table 2. Summary ORs and 95% CI of XPD Asp312Asn polymorphism and HNC risk.
Asn/Asn vs. Asp/Asp Asp/Asn vs. Asp/Asp Asn/Asn+Asp/Asn vs. Asp/Asp Asn/Asn vs. Asp/Asp+Asp/Asn
OR 95% CI PP
* OR 95% CI PP
* OR 95% CI PP
* OR 95% CI PP
*
Total 0.95 0.80–1.13 0.550 0.126 1.11 0.99–1.24 0.065 0.663 1.07 0.97–1.19 0.189 0.627 0.87 0.68–1.10 0.243 0.089
{
HWE 0.95 0.80–1.14 0.593 0.120 1.11 0.99–1.24 0.089 0.586 1.07 0.96–1.19 0.219 0.528 0.82 0.69–1.11 0.278 0.082
{
Ethnicity
Asian 1.20 0.73–2.00 0.470 0.213 1.14 0.87–1.50 0.345 0.649 1.14 0.88–1.48 0.328 0.951 1.16 0.71–1.89 0.546 0.216
Caucasian 0.92 0.76–1.11 0.366 0.121 1.11 0.98–1.25 0.110 0.468 1.06 0.94–1.19 0.317 0.430 0.83 0.64–1.08 0.165 0.085
{
Design
Hospital based 1.01 0.81–1.25 0.938 0.296 1.14 1.00–1.31 0.052 0.468 1.12 0.98–1.27 0.092 0.543 0.95 0.78–1.16 0.631 0.224
Population based 0.75 0.43–1.32 0.248 0.063
{ 1.04 0.85–1.28 0.684 0.692 0.98 0.81–1.19 0.865 0.611 0.73 0.42–1.28 0.271 0.045
{
*Test for heterogeneity.
{Estimates for random effects model.
doi:10.1371/journal.pone.0035220.t00
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idemonstrated that the 312 codon polymorphisms significantly
decrease the constitutive ERCC2 mRNA levels, especially in
smokers [24]. Hou et al. reported that the XPD 312 variant allele
may be associated with the reduced repair of aromatic DNA
adducts [25]. Matullo et al. proposed that exposure to environ-
mental carcinogens, such as polycyclic aromatic hydrocarbons
(PAHs), also accelerate cancer development through the codon
312 variant allele of XPD [26].
Correlations between the polymorphisms and some cancer risks
have been studied, but the results remain controversial. The XPD
Asp312Asn polymorphism has been shown to increase the risk of
bladder cancer and lung cancer, but it is not associated with breast
cancer [27–29].
The first study, published in 2002, revealed a borderline
correlation between XPD Asp312Asn polymorphism and HNC
risk in codominant model (for Asn/Asn vs. Asp/Asp: OR, 1.41;
95% CI: 1.01–1.97) [10]. To date, no consensus has been reached
on the correlation between XPD Asp312Asn polymorphism and
HNC risk. Majumder et al. [13] found that variant genotype (Asn/
Asn) at codon 312 of XPD is associated with increased risk of
Figure 2. Sensitivity analysis through deletion of one study at a time to reflect the influence of the individual dataset to the pooled
ORs in Asp/Asn vs. Asp/Asp model.
doi:10.1371/journal.pone.0035220.g002
Figure 3. Funnel plot analysis to detect publication bias for Asp/Asn vs. Asp/Asp genotype. Each point represents a separate study for
the indicated association.
doi:10.1371/journal.pone.0035220.g003
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CI=1.2–2.9). However, other studies showed that HNC risk is not
significantly related to XPD Asp312Asn polymorphism. Ji et al.
[17] found that the OR of the Asp312Asn polymorphism genotype
Asp/Asn is 1.94 (95% CI=0.92–4.08) relative to the Asp/Asp
genotype. Matullo et al. [11], An et al. [12], Harth et al. [14],
Abbasi et al. [15], and Jelonek et al. [16] also reported similar risks
of HNC.
The present meta-analysis of nine eligible studies, including
2670 cases and 4452 controls focused on XPD Asp312Asn
polymorphism and HNC risk, was performed to derive a more
precise estimate of the association, but no significant association
was found in the total population when all the studies were pooled.
Similarly, no significant association was detected in all genetic
models during the satisfied analysis based on the HWE, ethnicity
and study design. Our finding is not in accordance with that
previously published by Flores-Obando et al [19]. A marginally
significant association was observed between the XPD Asp312Asn
heterozygous and combined variants and HNC in their study. The
considerably larger sample size of our study may account for this
difference relative to the previous study.
Despite the considerable efforts to test for possible association
between XPD Asp312Asn polymorphism and HNC risk, some
limitations should be addressed. First, these results are based on
unadjusted estimates that lack the original data from the eligible
studies, which limits the evaluation of the effects of the gene-gene
and gene-environment interactions during HNC development.
Second, the sample size is still relatively small. Thus, we could not
have enough statistical data to find the true relationship between
XPD Asp312Asn polymorphism and HNC risk. Finally, each gene
is known to have a moderate effect on HNC development. The
combinations of certain genotypes may be more discriminating as
risk factors than a single locus genotype. In our meta-analysis,
linkage disequilibrium (LD) and haplotype analysis were not
performed. In spite of these limitations, no publication bias was
observed, and a large number of subjects still significantly
guarantee the statistical power of the analysis.
In conclusion, despite these limitations,our meta-analysis
suggests that XPD Asp312Asn polymorphism may not be
associated with HNC development. In the future, large-scale
case-control and population-based association studies are neces-
sary to validate the risks identified in the present meta-analysis and
to investigate the potential gene-gene and gene-environment
interactions between XPD Asp312Asn polymorphism and HNC
cancer.
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